We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
- Authors
Huffman, Mark D.; de Cates, Angharad N.; Ebrahim, Shah
- Abstract
<bold>Clinical Question: </bold>Is fixed-dose combination therapy (polypill) that combines antiplatelet, blood pressure-lowering, and cholesterol-lowering medications into a single pill associated with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal and nonfatal CVD events? Is the polypill associated with an increase in adverse events?<bold>Bottom Line: </bold>Polypills are associated with greater reductions in systolic blood pressure and total cholesterol compared with usual care, placebo, or active comparators, but also with a 19% higher risk of any adverse event. Due to limited power from available evidence, the association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain.
- Subjects
COMBINATION drug therapy; CARDIOVASCULAR disease treatment; SYSTOLIC blood pressure; BLOOD cholesterol; DRUG dosage
- Publication
JAMA: Journal of the American Medical Association, 2014, Vol 312, Issue 19, p2030
- ISSN
0098-7484
- Publication type
journal article
- DOI
10.1001/jama.2014.13616